New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
05:29 EDTPLXProtalix announces first patient treated in Phase I/II study of Fabry patients
Protalix BioTherapeutics announced that the first patient has been treated in the company's phase I/II clinical trial of Fabry patients with PRX-102. PRX-102 is the company's proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme in development as a long-term enzyme replacement therapy for the treatment of Fabry disease.
News For PLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
05:40 EDTPLXProtalix assumed with a Buy from Hold at Jefferies
Jefferies upgraded Protalix to Buy after assuming coverage of the name and raised its price target for shares to $2.60 from $2.00. The firm says Protalix's pipeline is growing beyond Elelyso.
April 20, 2015
16:40 EDTPLXCamber Capital reports 5.37% passive stake in Protalix

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use